Onkos Surgical entered into a definitive agreement with Stryker to acquire the Juvenile Tumour System (JTS). The system enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.
Onkos is focused on developing solutions for surgeons who specialize in musculoskeletal oncology and other complex orthopedic conditions.
JTS is a device that allows for non-invasive lengthening of the implant post-surgery over time in a clinical setting. The design eliminates the need for multiple lengthening surgeries, anesthesia or sedation, and therefore helps reduce the risk of complications and cost associated with limb reconstruction surgery.
“This is a significant day for Onkos Surgical and the musculoskeletal oncology community,” said Patrick Treacy, Co-Founder and CEO. “Our ‘Why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission. We are committed to being good stewards of the technology.
Onkos Surgical entered into a definitive agreement with Stryker to acquire the Juvenile Tumour System (JTS). The system enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.
Onkos is focused on developing solutions for surgeons who...
Onkos Surgical entered into a definitive agreement with Stryker to acquire the Juvenile Tumour System (JTS). The system enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.
Onkos is focused on developing solutions for surgeons who specialize in musculoskeletal oncology and other complex orthopedic conditions.
JTS is a device that allows for non-invasive lengthening of the implant post-surgery over time in a clinical setting. The design eliminates the need for multiple lengthening surgeries, anesthesia or sedation, and therefore helps reduce the risk of complications and cost associated with limb reconstruction surgery.
“This is a significant day for Onkos Surgical and the musculoskeletal oncology community,” said Patrick Treacy, Co-Founder and CEO. “Our ‘Why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and challenging procedures, and the JTS extendible prosthesis is a solution in service of this mission. We are committed to being good stewards of the technology.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
